| __timestamp | Agios Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 40786000 |
| Thursday, January 1, 2015 | 35992000 | 47876000 |
| Friday, January 1, 2016 | 50714000 | 52035000 |
| Sunday, January 1, 2017 | 71124000 | 55348000 |
| Monday, January 1, 2018 | 114145000 | 65276000 |
| Tuesday, January 1, 2019 | 132034000 | 82720000 |
| Wednesday, January 1, 2020 | 149070000 | 89118000 |
| Friday, January 1, 2021 | 121445000 | 181193000 |
| Saturday, January 1, 2022 | 121673000 | 174078000 |
| Sunday, January 1, 2023 | 119903000 | 184232000 |
Unlocking the unknown
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Veracyte, Inc. and Agios Pharmaceuticals, Inc. have demonstrated distinct spending patterns. From 2014 to 2023, Veracyte's SG&A expenses surged by approximately 350%, peaking in 2023. This reflects their aggressive market expansion and investment in operational infrastructure. In contrast, Agios Pharmaceuticals saw a more moderate increase of around 525% over the same period, with a peak in 2020. This suggests a strategic pivot towards optimizing operational efficiency. Notably, Veracyte's spending overtook Agios in 2021, indicating a shift in market dynamics. These trends highlight the importance of strategic financial management in sustaining growth and competitiveness in the biotech sector.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Veracyte, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.
Amneal Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.